1. Home
  2. HTH vs IMCR Comparison

HTH vs IMCR Comparison

Compare HTH & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hilltop Holdings Inc.

HTH

Hilltop Holdings Inc.

HOLD

Current Price

$34.31

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$34.82

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTH
IMCR
Founded
1998
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
HTH
IMCR
Price
$34.31
$34.82
Analyst Decision
Hold
Buy
Analyst Count
2
9
Target Price
$34.00
$67.00
AVG Volume (30 Days)
378.3K
269.1K
Earning Date
01-29-2026
11-06-2025
Dividend Yield
2.09%
N/A
EPS Growth
53.28
N/A
EPS
2.50
N/A
Revenue
$1,259,399,000.00
$379,590,000.00
Revenue This Year
N/A
$32.28
Revenue Next Year
$1.64
$10.66
P/E Ratio
$13.79
N/A
Revenue Growth
7.66
28.11
52 Week Low
$26.67
$23.15
52 Week High
$36.14
$40.72

Technical Indicators

Market Signals
Indicator
HTH
IMCR
Relative Strength Index (RSI) 47.33 40.33
Support Level $34.27 $35.41
Resistance Level $35.37 $36.64
Average True Range (ATR) 0.56 1.51
MACD -0.12 -0.25
Stochastic Oscillator 6.62 3.99

Price Performance

Historical Comparison
HTH
IMCR

About HTH Hilltop Holdings Inc.

Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: